Stock 1477 OCUMENSION THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ocumension Therapeutics

Equities

1477

KYG674111011

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:07 2024-07-05 am EDT 		5-day change 1st Jan Change
6.7 HKD +0.15% Intraday chart for Ocumension Therapeutics -2.19% +0.30%
Apr. 15 Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug MT
Apr. 15 Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
PR
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
AQ
Ocumension Therapeutics Announces 2023 Interim Results
AQ
Nicox's Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
AQ
Nicox, 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023
AQ
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China
AQ
Ocumension Therapeutics Announces 2022 Annual Results
AQ
Nicox to Present at Upcoming Scientific Conferences
AQ
Nicox to Participate in Financial Pharmaceutical Industry and Scientific Events in H1 2023
AQ
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
AQ
Ocumension Therapeutics : INSIDE INFORMATION NEW DRUG APPLICATION OF OUR CORE PRODUCT OT-401 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
PU
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
AQ
Ocumension Therapeutics : Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength
PR
Ocumension Therapeutics : Announces 2021 Interim Results
PR
Ocumension Therapeutics : NOTICE OF EXTRAORDINARY GENERAL MEETING
PU
OPKO Health : to Develop and Commercialize RAYALDEE in Greater China with Nicoya Therapeutics
AQ
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT IND APPLICATION RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN CHINA
PU
Ocumension Therapeutics : COMPLETION OF THE TRANSACTIONS UNDER SHARE PURCHASE AGREEMENT
PU
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT APPROVAL FOR COMMENCEMENT OF INITIAL PEDIATRIC STUDY PLAN FOR OT-101 IN THE UNITED STATES
PU
Ocumension Therapeutics : (I) DISCLOSEABLE TRANSACTIONS RELATING TO THE EXCLUSIVE LICENSE AGREEMENT AND THE SHARE PURCHASE AGREEMENT AND (II) THE WARRANT SUBSCRIPTION AGREEMENT WITH ALIMERA SCIENCES, INC.
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1477 Stock
  4. News Ocumension Therapeutics
  5. Press Releases